These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37631269)

  • 21. Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infection.
    Sun Z; Wang Q; Jia R; Xia S; Li Y; Liu Q; Xu W; Xu J; Du L; Lu L; Jiang S
    Viruses; 2015 Feb; 7(2):798-819. PubMed ID: 25690799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Formulation and in vitro evaluation of in situ gels containing secnidazole for vaginitis.
    Narayana RC; Harish NM; Gulzar A M; Prabhakara P; Singh AK; Subrahmanyam EV
    Yakugaku Zasshi; 2009 May; 129(5):569-74. PubMed ID: 19420887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, vs its achievable concentrations in the human respiratory tract and comparison to ribavirin.
    Kim YI; Pareek R; Murphy R; Harrison L; Farrell E; Cook R; DeVincenzo J
    Influenza Other Respir Viruses; 2017 Nov; 11(6):525-530. PubMed ID: 28990339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and Development of Thermoreversible Ophthalmic In Situ Hydrogel of Moxifloxacin HCl.
    Shastri DH; Prajapati ST; Patel LD
    Curr Drug Deliv; 2010 Jul; 7(3):238-43. PubMed ID: 20497100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of Moxifloxacin Hydrochloride loaded
    Swain GP; Patel S; Gandhi J; Shah P
    J Oral Biol Craniofac Res; 2019; 9(3):190-200. PubMed ID: 31080718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fabrication of an ionic-sensitive in situ gel loaded with resveratrol nanosuspensions intended for direct nose-to-brain delivery.
    Hao J; Zhao J; Zhang S; Tong T; Zhuang Q; Jin K; Chen W; Tang H
    Colloids Surf B Biointerfaces; 2016 Nov; 147():376-386. PubMed ID: 27566226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing ophthalmic delivery of a poorly water soluble drug from an aqueous in situ gelling system.
    Senjoti FG; Timmins P; Conway BR; Smith AM
    Eur J Pharm Biopharm; 2020 Sep; 154():1-7. PubMed ID: 32599271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thermoreversible Carbamazepine In Situ Gel for Intranasal Delivery: Development and In Vitro, Ex Vivo Evaluation.
    Mohananaidu K; Chatterjee B; Mohamed F; Mahmood S; Hamed Almurisi S
    AAPS PharmSciTech; 2022 Oct; 23(8):288. PubMed ID: 36271212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucoadhesive in situ forming gel for oral mucositis pain control.
    Li T; Bao Q; Shen J; Lalla RV; Burgess DJ
    Int J Pharm; 2020 Apr; 580():119238. PubMed ID: 32194210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 18β-Glycyrrhetinic acid inhibits the apoptosis of cells infected with rotavirus SA11 via the Fas/FasL pathway.
    Wang X; Xie F; Zhou X; Chen T; Xue Y; Wang W
    Pharm Biol; 2021 Dec; 59(1):1098-1105. PubMed ID: 34411493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation.
    Galgatte UC; Kumbhar AB; Chaudhari PD
    Drug Deliv; 2014 Feb; 21(1):62-73. PubMed ID: 24191774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hp-β-CD-voriconazole in situ gelling system for ocular drug delivery: in vitro, stability, and antifungal activities assessment.
    Pawar P; Kashyap H; Malhotra S; Sindhu R
    Biomed Res Int; 2013; 2013():341218. PubMed ID: 23762839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formulation development of ambroxol hydrochloride soft gel with application of statistical experimental design and response surface methodology.
    Dabhi M; Gohel M; Parikh R; Sheth N; Nagori S
    PDA J Pharm Sci Technol; 2011; 65(1):20-31. PubMed ID: 21414937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages.
    Sake SM; Kosch C; Blockus S; Haid S; Gunesch AP; Zhang X; Friesland M; Trummer SB; Grethe C; Kühnel A; Rückert J; Duprex WP; Huang J; Rameix-Welti MA; Empting M; Fischer N; Hirsch AKH; Schulz TF; Pietschmann T
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0103222. PubMed ID: 36346232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formulation and evaluation of an in situ gel-forming ophthalmic formulation of moxifloxacin hydrochloride.
    Mandal S; Thimmasetty MK; Prabhushankar G; Geetha M
    Int J Pharm Investig; 2012 Apr; 2(2):78-82. PubMed ID: 23119236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological Characterization of TP0591816, a Novel Macrocyclic Respiratory Syncytial Virus Fusion Inhibitor with Antiviral Activity against F Protein Mutants.
    Yoshida I; Arikawa K; Honma Y; Inatani S; Yoshinaga M; Sugiyama H
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.
    Perron M; Stray K; Kinkade A; Theodore D; Lee G; Eisenberg E; Sangi M; Gilbert BE; Jordan R; Piedra PA; Toms GL; Mackman R; Cihlar T
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1264-73. PubMed ID: 26666922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imiquimod suppresses respiratory syncytial virus (RSV) replication via PKA pathway and reduces RSV induced-inflammation and viral load in mice lungs.
    Salinas FM; Nebreda AD; Vázquez L; Gentilini MV; Marini V; Benedetti M; Nabaes Jodar MS; Viegas M; Shayo C; Bueno CA
    Antiviral Res; 2020 Jul; 179():104817. PubMed ID: 32387475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication
    Jorquera PA; Mathew C; Pickens J; Williams C; Luczo JM; Tamir S; Ghildyal R; Tripp RA
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30541831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Innovative sprayable in situ gelling fluticasone suspension: Development and optimization of nasal deposition.
    Nižić L; Ugrina I; Špoljarić D; Saršon V; Kučuk MS; Pepić I; Hafner A
    Int J Pharm; 2019 May; 563():445-456. PubMed ID: 30965121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.